# COVID-19 vaccination and mortality among coronary care patients with severe acute respiratory infection in Bangladesh: a prospective study (2021–2024)

**Authors:** Zubair Akhtar, Md Ariful Islam, Mohammad Abdul Aleem, Tanzir Ahmed Shuvo, Md Zakiul Hassan, Asadullah, Mustafizur Rahman, Mohammed Ziaur Rahman, Mohammad Enayet Hossain, Tahmina Shirin, Mahbubur Rahman, Manjur Hossain Khan Jony, Monalisa, Ferdous Rahman Sarker, Ahmed Nawsher Alam, Shah Niaz Md. Rubaid Anwar, Mahmudur Rahman, Awachana Jiamsakul, Aye M. Moa, Timothy C. Tan, Ole Fröbert, Fahmida Chowdhury, C Raina MacIntyre

PMC · DOI: 10.1016/j.lansea.2026.100745 · The Lancet Regional Health - Southeast Asia · 2026-03-02

## TL;DR

This study found that COVID-19 vaccination was linked to lower mortality in Bangladeshi patients with severe respiratory infections and heart complications.

## Contribution

The study provides new evidence on the protective effect of COVID-19 vaccination in reducing mortality among patients with cardiovascular complications and SARI in Bangladesh.

## Key findings

- Vaccinated patients had an 89.6% survival rate compared to 81.4% in unvaccinated patients.
- AMI was associated with higher mortality, while vaccination was protective against all-cause mortality.
- SARS-CoV-2 and influenza were detected in 6.8% and 4.8% of patients, respectively.

## Abstract

COVID-19 increases cardiovascular risk, and vaccination reduces adverse outcomes and mortality. We analysed national hospital-based sentinel surveillance data from Bangladesh, and the aim of the study was to identify factors associated with all-cause mortality among patients with cardiovascular complications.

We included patients from coronary care units in nine tertiary-hospitals between February 2021 and December 2024 with severe acute respiratory infections (SARI). Nasopharyngeal and oropharyngeal swabs were tested for SARS-CoV-2 and influenza viruses by multiplex rRT-PCR. Patients were followed up from hospital admission to 30 days post-discharge. Survival was assessed with Kaplan–Meier estimates stratified by vaccination status and compared using log-rank test. Risk factors for all-cause mortality were analysed using multivariable Cox proportional hazards regression, stratified by hospital type.

We enrolled 396 patients (median age 60, IQR: 48–65 years), and 70.5% (279/396) were male. The Median follow-up time was 33 days (IQR: 32–34 days). There were 13.9% (55/396) deaths, 41.2% (163/396) had acute myocardial infarction (AMI) and 71.2% (286/396) were COVID-19 vaccinated patients. SARS-CoV-2 and influenza viruses were detected among 6.8% (27/396) and 4.8% (19/396) patients, respectively. At follow-up, the survival rate was 89.6% in COVID-19 vaccinated patients compared to 81.4% in unvaccinated patients (P-value = 0.041). AMI was associated with higher mortality [HR = 1.74, (95% CI: 1.01–3.02), P-value = 0.048] while COVID-19 vaccination was protective [HR = 0.55, (95% CI: 0.32–0.96), P-value = 0.037].

COVID-19 vaccination was associated with reduced all-cause deaths among SARI patients with cardiovascular complications.

Centres for Disease Control and Prevention (CDC), Atlanta, Georgia, USA (U01GH002259). ZA is supported by UNSW by a UIPA PhD scholarship.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096), acute myocardial infarction (MONDO:0004781)

## Full-text entities

- **Diseases:** SARI (MESH:D045169), heart failure (MESH:D006333), cardiac condition (MESH:D006331), AMI (MESH:D009203), infection (MESH:D007239), cardiovascular complications (MESH:D002318), COVID (MESH:D000086382), ischaemic stroke (MESH:D002544), cough (MESH:D003371), death (MESH:D003643), fever (MESH:D005334), autoimmune diseases (MESH:D001327), pneumonia (MESH:D011014), sudden cardiac death (MESH:D016757), dyspnea (MESH:D004417), malignancy (MESH:D009369), cardiac arrest (MESH:D006323), respiratory infection (MESH:D012141), HBIS (MESH:D007251)
- **Chemicals:** Oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606], Orthomyxoviridae (family) [taxon 11308], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], H3N2 subtype (serotype) [taxon 119210]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12969467/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12969467/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12969467/full.md

---
Source: https://tomesphere.com/paper/PMC12969467